Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
- PMID: 32982251
- PMCID: PMC7509325
- DOI: 10.2147/NDT.S263537
Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
Abstract
Purpose: Benzodiazepines (BZDs) are prescribed to treat psychiatric diseases. However, many guidelines recommend limiting the use of BZDs because of side effects and lack of evidence regarding long-term efficacy. Moreover, reducing BZDs' use is difficult because of dependency and the severity of withdrawal symptoms. The efficacy of cognitive behavioral therapy (CBT) for mood and anxiety disorders has been demonstrated. However, there is scant evidence that CBT has effectively reduced BZDs use, especially in Japan, where the BZDs prescription rate is high. Therefore, we sought to examine the impact of CBT on reducing BZDs use in a Japanese psychiatric setting.
Patients and methods: Participants were outpatients with mood and anxiety disorders who were prescribed BZD anxiolytics. We retrospectively reviewed changes in BZD anxiolytics prescription dosages during CBT (66 patients; mean number of CBT sessions, 14.6) from our hospital record between April 2015 and September 2017. We checked prescriptions at four time points: at first interview for judging adaptation of CBT (baseline), at the first CBT session, at the last CBT session, and 3 months after the last CBT session.
Results: A total of 13 of 66 patients discontinued BZD anxiolytics during CBT, and 21 of 66 reduced their prescribed dosage by 50%. The association between discontinuation and dose-reduction and assessment period was modeled simultaneously using Bayesian hierarchical hurdle model. Results from the modeling showed a significant discontinuation at post-CBT and at 3 months post-CBT session compared to baseline (estimated median odds ratio [OR] post-CBT = 9.79 [95% CI: 4.65-20.45]; OR at 3 months post-CBT = 11.53 [95% CI: 6.06-22.33]). Moreover, a significant dose reduction was observed post-intervention (estimated median relative risk = 0.845 [95% CI: 0.729-0.982]), with a median reduction of 1.7 mg (diazepam conversion) in BZD use.
Conclusion: Our results suggest that CBT possibly aids in reducing and discontinuing BZD anxiolytics use for Japanese patients.
Keywords: acquired dependency; depression; discontinuation; psychiatric diseases.
© 2020 Nakajima et al.
Conflict of interest statement
The authors have no financial disclosures or other conflicts of interest to declare.
Figures

Similar articles
-
Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta-analysis.Psychiatry Clin Neurosci. 2021 Apr;75(4):119-127. doi: 10.1111/pcn.13195. Epub 2021 Feb 25. Psychiatry Clin Neurosci. 2021. PMID: 33448517 Free PMC article.
-
Attitudes and Difficulties Associated with Benzodiazepine Discontinuation.Int J Environ Res Public Health. 2022 Nov 30;19(23):15990. doi: 10.3390/ijerph192315990. Int J Environ Res Public Health. 2022. PMID: 36498061 Free PMC article.
-
Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.PLoS Med. 2018 Aug 7;15(8):e1002635. doi: 10.1371/journal.pmed.1002635. eCollection 2018 Aug. PLoS Med. 2018. PMID: 30086134 Free PMC article.
-
Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.Front Psychiatry. 2023 May 12;14:1083568. doi: 10.3389/fpsyt.2023.1083568. eCollection 2023. Front Psychiatry. 2023. PMID: 37252154 Free PMC article.
-
Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis.Sleep Med Rev. 2019 Dec;48:101214. doi: 10.1016/j.smrv.2019.101214. Epub 2019 Oct 1. Sleep Med Rev. 2019. PMID: 31648145
Cited by
-
Trends in the Prescription of Benzodiazepine Receptor Agonists from 2009 to 2020: A Retrospective Study Using Electronic Healthcare Record Data of a University Hospital in Japan.Healthcare (Basel). 2021 Dec 13;9(12):1724. doi: 10.3390/healthcare9121724. Healthcare (Basel). 2021. PMID: 34946449 Free PMC article.
-
Characteristics of patients with anxiety disorder without selective serotonin reuptake inhibitor prescription over a two-year period of pharmacotherapy.Neuropsychopharmacol Rep. 2024 Mar;44(1):67-72. doi: 10.1002/npr2.12379. Epub 2023 Sep 21. Neuropsychopharmacol Rep. 2024. PMID: 37735810 Free PMC article.
References
-
- Lader M. Benzodiazepines revisited–will we ever learn? Addiction. 2011;106(12):2086–2109. - PubMed
-
- Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774–782. doi:10.1177/0269881107077355 - DOI - PubMed
-
- van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997;185(8):510–516. doi:10.1097/00005053-199708000-00006 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous